Pharmacokinetic Drug –Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer
ConclusionsCo-administration of apalutamide with CYP3A4, CYP2C19, CYP2C9, P-gp, BCRP or OATP1B1 substrates may cause loss of activity for these medications. Therefore, appropriate mitigation strategies are recommended.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Actos | Allegra | Breast Cancer | Cancer | Cancer & Oncology | Coumadin | Crestor | Drugs & Pharmacology | Fexofenadine | Gemfibrozil | Omeprazole | Organic | Prilosec | Prostate Cancer | Rosuvastatin | Study | Warfarin